Abbott Explains Biologic Medicines and Biosimilars
Abbott Laboratories is clarifying the roles of biologic medicines and their lower-cost counterparts, biosimilars. The company suggests biosimilars can significantly improve access to treatments and reduce healthcare costs.
Biologic medicines, derived from living organisms, have transformed the treatment landscape for diseases ranging from cancer to diabetes. Abbott Laboratories is providing insight into the evolution of these complex therapies and how biosimilars are enhancing their accessibility.
Historically, biologics like insulin were sourced from animals. However, advancements in biotechnology now enable their production using genetically engineered cells, such as bacteria and yeast. While biologics offer sophisticated treatment options, their high development and manufacturing costs have historically limited access, particularly in emerging markets.
Biosimilars, developed to be highly similar to an already approved biologic, present a solution to rising costs. Abbott suggests that biosimilars can lower treatment expenses, thereby broadening access to these vital therapies. These medications undergo rigorous evaluation by regulatory bodies, ensuring they offer comparable safety and efficacy to their originator counterparts.
Matthias Mueller, head of Innovation and Development in Abbott's medicines business, stated that the adoption of biosimilars worldwide has led to substantial cost savings and improved patient outcomes. Evidence from European healthcare systems and studies in China support these claims. Abbott highlights that ensuring access to biosimilars in developing countries is crucial for disease management and promoting global health.
The increased availability of biosimilars has the potential to bridge gaps in healthcare access, enabling more individuals globally to live healthier, longer lives. Abbott emphasizes its role in facilitating the broader availability and utilization of these critical medicines.